Alkem Laboratories Ltd
ALKEM NSE
Alkem Laboratories Ltd
Healthcare F&ONSE: ALKEM BSE: 539523 Pharmaceuticals
Key Fundamentals
MidcapPharmaceuticalsHealthcareMarket Cap
₹64,798 Cr
Volatility
Moderate
P/E Ratio
28.31
EBITDA
₹3,589 Cr
Return on Equity
16.4%
Debt to Equity
0.15
Book Value
₹1,155.87
EPS
₹179.8
52W High
₹5,933.5
52W Low
₹4,822
Insights
BetaAI-extracted from concalls & annual reports · figures as reported, with sources
Log in to view Alkem Laboratories Ltd insights
68 extracted metrics + investor summaries across FY09–FY26.
Tapetide Score
Data-driven rating, 0–100. How it works →
Technical Indicators
Key Insights
Strengths
1- Company has been maintaining a healthy dividend payout of 26.3%
Weaknesses
2- Promoter holding has decreased over last quarter: -1.50%
- The company has delivered a poor sales growth of 10.7% over past five years.
Growth Rate
Revenue Growth
13.65% ↗
Net Income Growth
6.19% ↗
Cash Flow Change
2.62% ↗
ROE
-7.97% ↗
ROCE
-2.33% ↗
EBITDA Margin (Avg.)
5.06% ↗
AI Analysis — Bull vs Bear
anthropic claude-opus-4.6 10h agoAI opinion · based on fundamentals
Risk medium
Alkem Laboratories trades at a market cap of ₹64,798 Cr with a P/E of 27.8x. FY25 revenue stood at ₹12,965 Cr (up 2.3% YoY) with EBITDA margins expanding from 17.7% to 19.4%, while the company has delivered a 3-year profit CAGR of 32% driven by margin recovery after a weak FY23. The India business (69% of sales) continues to grow steadily but international sales have been volatile.
Bull Case 8
- Strong 3-year compounded profit growth of 32% CAGR, indicating significant earnings recovery and margin expansion
- EBITDA margin expanded from 17.7% in FY24 to 19.4% in FY25, a 170 bps improvement reflecting cost optimization
- Consistent ROE of 18-19% over 3, 5, and 10-year periods demonstrates efficient capital allocation
- India domestic business contributes 68.7% of revenue and grew 6% YoY in 9M FY25, providing stability from a large addressable market
- 18 brands feature in the Top 300 brands in the Indian Pharmaceutical Market with leadership in anti-infectives segment
- Trade generics segment accounts for ~20% of domestic business and is growing at 14-15% annually, offering diversification
- Chronic therapy segment now contributes approximately 18% of total prescription portfolio, indicating successful pivot toward higher-margin therapies
- Healthy dividend payout ratio of 26.3% with a current yield of 0.97%, providing income return to shareholders
Bear Case 8
- FY25 revenue growth was only 2.3% YoY (₹12,965 Cr vs ₹12,673 Cr), sharply below the 10-year sales CAGR of 12%
- International sales declined 7.7% YoY in the first nine months of FY25 (₹28,463 Mn vs ₹30,837 Mn), reflecting US pricing pressure
- P/E of 27.8x is elevated relative to the 5-year compounded profit CAGR of only 9%, implying limited margin of safety
- Promoter holding decreased by 1.50% in the last quarter, signaling potential insider caution
- 5-year compounded sales growth of only 10.7-11% is below the broader Indian pharma sector average, indicating market share challenges
- Stock price CAGR of just 2% over 1 year and 8% over 5 years has significantly underperformed the broader market
- P/B ratio of 4.73x is rich for a company with sub-20% ROE, limiting valuation re-rating potential
- Q4 FY25 EBITDA margin of 12.4% was below Q4 FY24's 13.7%, showing quarterly margin volatility despite annual improvement
This is AI-generated analysis, not financial advice. Do your own due diligence.
AI News Digest
anthropic claude-opus-4.6 4h ago Positives 3
- Q1FY27 profit surges 48% YoY Jul 30
Standalone net profit rose 48% YoY to ₹432.10 crore for Q1FY27, with revenue jumping 25% to ₹3,444.70 crore.
- New SVP Marketing & Sales hired Aug 3
Rajpal Singh Rana appointed as SVP - Marketing & Sales effective August 3, 2026, bringing 30+ years of pharma experience.
- GHG emissions cut 15% in FY26 Jul 29
Scope 1 and 2 emissions reduced 15% in FY26, energy consumption dropped 22%, and 4,376 MT of plastic waste was recycled.
Neutral 5
- ₹1,100 Cr Alkem Medtech investment Jul 17
Acquired 79.36 crore equity shares in Alkem Medtech for ₹1,100 crore to fund a stake in Occlutech Holding AG.
- Block trades worth ₹139 Cr Jul 15
Institutional block trades of ~1.82 lakh shares at ₹5,627 on BSE and ~64,869 shares at ₹5,679 on NSE, totalling ₹139.25 crore.
- EGM for Adroit Biomed amalgamation Jul 15
EGM scheduled for August 17, 2026 to approve scheme of amalgamation with wholly-owned subsidiary Adroit Biomed Limited via NCLT order.
- Q1FY27 earnings call on Aug 14 Jul 27
Conference call scheduled for August 14, 2026 at 4:30 PM IST, hosted by Motilal Oswal Securities.
- Senior VP resignation accepted Jul 23
Dr. Jitendra Singh Huda resigned as Senior VP effective July 23, 2026 to pursue other professional opportunities.
TL;DR: Alkem Laboratories is delivering strong financial performance with 48% profit growth and 25% revenue expansion in Q1FY27, supported by solid ESG progress. The ₹1,100 crore Medtech investment signals expansion into medical devices via Occlutech. No material headwinds are visible in recent news flow, and the trend is clearly improving with robust earnings momentum heading into FY27.
Quarterly Results
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 2,903 | 2,968 | 3,440 | 3,324 | 2,936 | 3,032 | 3,415 | 3,374 | 3,144 | 3,371 | 4,001 | 3,737 | 3,603 |
| Expenses | 2,549 | 2,579 | 2,693 | 2,616 | 2,534 | 2,423 | 2,662 | 2,615 | 2,752 | 2,632 | 3,080 | 2,909 | 3,086 |
| Operating Profit | 353 | 389 | 747 | 708 | 402 | 609 | 753 | 759 | 391 | 739 | 921 | 828 | 517 |
| OPM % | 12% | 13% | 22% | 21% | 14% | 20% | 22% | 23% | 12% | 22% | 23% | 22% | 14% |
| Other Income | -34 | 66 | 6 | 42 | 76 | 120 | 134 | 93 | 146 | 149 | 104 | 90 | 65 |
| Interest | 29 | 30 | 30 | 25 | 27 | 29 | 28 | 36 | 28 | 30 | 35 | 42 | 54 |
| Depreciation | 78 | 72 | 74 | 70 | 83 | 80 | 79 | 85 | 112 | 88 | 94 | 95 | 106 |
| PBT | 212 | 353 | 648 | 655 | 367 | 619 | 780 | 731 | 396 | 771 | 896 | 781 | 423 |
| Tax % | 68% | 18% | 5% | 8% | 17% | 11% | 10% | 12% | 18% | 13% | 13% | 16% | 40% |
| Net Profit | 68 | 288 | 615 | 604 | 304 | 550 | 702 | 641 | 322 | 668 | 779 | 653 | 251 |
| EPS in Rs | 5.94 | 23.98 | 51.9 | 49.76 | 24.55 | 45.6 | 57.6 | 52.34 | 25.58 | 55.56 | 63.99 | 53.19 | 19.78 |
Profit & Loss
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 3,674 | 4,905 | 5,688 | 6,401 | 7,357 | 8,344 | 8,865 | 10,634 | 11,599 | 12,668 | 12,965 | 14,712 |
| Expenses | 3,248 | 4,038 | 4,687 | 5,392 | 6,237 | 6,868 | 6,920 | 8,580 | 9,977 | 10,419 | 10,452 | 11,706 |
| Operating Profit | 427 | 866 | 1,001 | 1,009 | 1,120 | 1,476 | 1,945 | 2,054 | 1,622 | 2,249 | 2,512 | 3,007 |
| OPM % | 12% | 18% | 18% | 16% | 15% | 18% | 22% | 19% | 14% | 18% | 19% | 20% |
| Other Income | 176 | 227 | 110 | 115 | 82 | 102 | 230 | 146 | 101 | 186 | 494 | 407 |
| Interest | 81 | 71 | 45 | 55 | 55 | 65 | 59 | 52 | 107 | 112 | 122 | 161 |
| Depreciation | 71 | 93 | 101 | 143 | 193 | 253 | 275 | 304 | 310 | 299 | 357 | 382 |
| PBT | 451 | 928 | 965 | 926 | 955 | 1,260 | 1,842 | 1,844 | 1,305 | 2,023 | 2,527 | 2,871 |
| Tax % | 13% | 19% | 6% | 31% | 19% | 9% | 12% | 9% | 23% | 10% | 12% | 18% |
| Net Profit | 392 | 752 | 905 | 638 | 774 | 1,149 | 1,618 | 1,680 | 1,007 | 1,811 | 2,215 | 2,351 |
| EPS in Rs | 32.75 | 62.02 | 74.61 | 52.77 | 63.61 | 94.26 | 133 | 138 | 82.31 | 150 | 181 | 193 |
| Div. Payout % | 12% | 20% | 20% | 25% | 25% | 27% | 23% | 25% | 61% | 27% | 25% | 28% |
Balance Sheet
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 | 24 |
| Reserves | 2,975 | 3,668 | 4,444 | 4,840 | 5,415 | 6,137 | 7,353 | 8,614 | 9,021 | 10,288 | 11,961 | 13,796 |
| Borrowings | 1,306 | 658 | 659 | 998 | 944 | 1,616 | 1,707 | 2,668 | 1,397 | 1,418 | 1,381 | 2,047 |
| Other Liabilities | 986 | 1,184 | 1,440 | 1,803 | 1,824 | 2,169 | 2,435 | 2,763 | 3,315 | 3,844 | 4,325 | 4,991 |
| Total Liabilities | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,858 |
| Fixed Assets | 1,374 | 1,450 | 1,797 | 2,284 | 2,530 | 2,908 | 2,793 | 2,902 | 2,683 | 2,873 | 2,852 | 3,871 |
| CWIP | 111 | 172 | 299 | 381 | 493 | 363 | 393 | 339 | 323 | 159 | 548 | 282 |
| Investments | 481 | 509 | 553 | 444 | 324 | 261 | 333 | 371 | 622 | 484 | 1,846 | 1,869 |
| Other Assets | 3,325 | 3,403 | 3,918 | 4,555 | 4,861 | 6,413 | 8,000 | 10,457 | 10,129 | 12,060 | 12,445 | 14,836 |
| Total Assets | 5,291 | 5,534 | 6,568 | 7,664 | 8,208 | 9,946 | 11,519 | 14,069 | 13,757 | 15,575 | 17,691 | 20,858 |
Cash Flow
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating | 325 | 726 | 471 | 266 | 780 | 585 | 1,265 | 1,111 | 1,682 | 1,948 | 1,913 | 1,963 |
| Investing | -235 | 205 | -294 | -351 | -318 | -737 | -995 | -1,433 | 120 | -1,011 | -1,288 | -1,682 |
| Financing | -52 | -927 | -138 | 85 | -379 | 79 | -272 | 380 | -1,761 | -1,145 | -811 | -503 |
| Net Cash Flow | 39 | 3 | 40 | 0 | 82 | -73 | -2 | 58 | 42 | -207 | -186 | -222 |
| Free Cash Flow | 190 | 472 | -163 | -411 | 253 | 237 | 1,116 | 783 | 1,453 | 1,761 | 1,278 | 1,476 |
| CFO/OP | 101 | 107 | 73 | 47 | 92 | 59 | 86 | 73 | 121 | 105 | 96 | 86 |
Ratios
| Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 52 | 42 | 46 | 62 | 62 | 72 | 66 | 65 | 67 | 65 | 69 | 74 |
| Inventory Days | 169 | 169 | 198 | 221 | 186 | 198 | 241 | 262 | 194 | 197 | 224 | 239 |
| Days Payable | 101 | 108 | 122 | 147 | 119 | 104 | 112 | 102 | 87 | 129 | 148 | 161 |
| Cash Conversion Cycle | 121 | 103 | 122 | 135 | 129 | 167 | 196 | 225 | 174 | 132 | 145 | 152 |
| Working Capital Days | -52 | 13 | 34 | 40 | 55 | 44 | 48 | 31 | 66 | 135 | 123 | 123 |
| ROCE % | 12% | 23% | 21% | 17% | 16% | 18% | 22% | 18% | 14% | 20% | 20% | 21% |
Documents
1
US FDA Inspection At Company'S Manufacturing Facility Located At Amaliya, Daman
2 May - US FDA inspected Daman facility from 20 Apr to 1 May 2026, issuing Form 483 with seven observations. 2 May - US FDA inspected Daman facility from 20 Apr to 1 May 2026, issuing Form 483 with seven observations.
2
Announcement under Regulation 30 (LODR)-Press Release / Media Release
8 May - US FDA inspected Taloja CRO facility on 8 May 2026; no Form 483 issued. 8 May - US FDA inspected Taloja CRO facility on 8 May 2026; no Form 483 issued.
3
US FDA Inspection At Company'S Manufacturing Facility Located At Amaliya, Daman
2 May - US FDA inspected Daman facility from 20 Apr to 1 May 2026, issuing Form 483 with seven observations. 2 May - US FDA inspected Daman facility from 20 Apr to 1 May 2026, issuing Form 483 with seven observations.
4
Regulation 30 Of SEBI (LODR) Regulations, 2015.
5 May - Commissioner (Appeals) dropped Rs 69.65 crore GST demand, interest and penalty; order received 4 May 2026. 5 May - Commissioner (Appeals) dropped Rs 69.65 crore GST demand, interest and penalty; order received 4 May 2026.
5
Announcement under Regulation 30 (LODR)-Cessation
24 Apr - Dr. Vikas Gupta resigns as CEO; continues until 30 June 2026 for transition. 24 Apr - Dr. Vikas Gupta resigns as CEO; continues until 30 June 2026 for transition.
Frequently Asked Questions about Alkem Laboratories Ltd
What does Alkem Laboratories Ltd do?
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Where is Alkem Laboratories Ltd (ALKEM) listed?
Alkem Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: ALKEM and BSE: 539523. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Alkem Laboratories Ltd belong to?
Alkem Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the market capitalisation of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has a market capitalisation of approximately ₹64798.25 Cr. Based on this, it is classified as a Large Cap stock.
What is the PE ratio of Alkem Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Alkem Laboratories Ltd is 28.31. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Alkem Laboratories Ltd?
Over the past 52 weeks, Alkem Laboratories Ltd has traded between a low of ₹4,822 and a high of ₹5,933.5. This range helps investors understand the stock's price volatility and recent trading levels.
Does Alkem Laboratories Ltd pay dividends?
Yes, Alkem Laboratories Ltd has a dividend yield of 0.97%. Dividend yield indicates the annual dividend income relative to the share price. A consistent dividend history can signal financial stability.
What is the Return on Equity (ROE) of Alkem Laboratories Ltd?
Alkem Laboratories Ltd has a Return on Equity (ROE) of 16.40%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Alkem Laboratories Ltd on Tapetide?
On Tapetide, you can view Alkem Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.
Company Information
Alkem Laboratories is engaged in pharmaceutical business with global operations. The Company is engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products.(Source : 202003-01 Annual Report Page No:107)
Website alkemlabs.com
CEO Mr. Basudeo Narian Singh
Employees 18,785
Listed 2015-12-23
Face Value ₹ 2
Issued Size 11,95,65,000